<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174092</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL 2019/CGV/01</org_study_id>
    <secondary_id>2019.A01715-52</secondary_id>
    <nct_id>NCT04174092</nct_id>
  </id_info>
  <brief_title>Catastrophism in Chronic Inflammatory Rheumatism</brief_title>
  <acronym>CRIC</acronym>
  <official_title>Catastrophism in Chronic Inflammatory Rheumatism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catastrophic is defined as a negative cognitive and emotional response based on inadequate
      pain expression. It has three components: rumination, amplification and vulnerability. The
      assessment of catastrophism is carried out using a validated questionnaire called the &quot;Pain
      Catatrophizing Scale&quot; (PCS).

      Recent studies highlight the significant impact of catastrophism in neuromuscular and
      mechanical rheumatic diseases such as gonarthrosis gonalgia and low back pain. In these
      diseases, it has been shown that catastrophism has a negative impact both on the experience
      of pain and on the response to different types of treatments (medical and surgical). Several
      studies have implemented multidisciplinary management and in particular cognitive-behavioural
      therapy with an improvement in the pain experience in patients who are catastrophic.

      In chronic inflammatory rheumatic diseases such as rheumatoid arthritis, spondyloarthritis
      and psoriatic arthritis, the prevalence and impact of catastrophism is still poorly
      understood.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>catastrophic assessment</measure>
    <time_frame>Day 0</time_frame>
    <description>Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>catastrophic assessment</measure>
    <time_frame>at 3 months</time_frame>
    <description>Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>catastrophic assessment</measure>
    <time_frame>at 6 months</time_frame>
    <description>Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>catastrophic assessment</measure>
    <time_frame>at 12 months</time_frame>
    <description>Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Chronic Inflammatory Rheumatism</condition>
  <arm_group>
    <arm_group_label>rheumatoid arthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>spondyloarthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).
Patients will be seen at 3, 6 and 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriatic arthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).
Patients will be seen at 3, 6 and 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>completing self-questionnaires</intervention_name>
    <description>completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism</description>
    <arm_group_label>Psoriatic arthritis</arm_group_label>
    <arm_group_label>rheumatoid arthritis</arm_group_label>
    <arm_group_label>spondyloarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patients, hospital follow-up, with RA according to ACR 2010 criteria, or
             spondyloarthritis according to ASAS 2009 criteria or according to AMOR or psoriatic
             arthritis according to Caspar 2006 criteria.

          -  Patient who has given free and informed consent.

          -  Patient who has signed the consent form.

          -  Patient affiliated or benefiting from a health insurance plan.

          -  Adult patient (≥18 years old).

        Exclusion Criteria:

          -  Patient under the protection of justice, under guardianship or curatorship.

          -  Patient unable to express consent.

          -  Patient for whom it is impossible to provide informed information.

          -  Poor command and understanding of the French language making it impossible to complete
             self-questionnaires
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anissa MEGZARI</last_name>
    <role>Study Director</role>
    <affiliation>CHU de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cécile GAUJOUX VIALA</last_name>
    <phone>04 66 68 31 20</phone>
    <email>cecile.GAUJOUX.VIALA@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte TRAVERSON</last_name>
    <phone>04 66 68 31 20</phone>
    <email>charlotte.traverson@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34 295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric LUKAS</last_name>
      <phone>04 67 33 73 11</phone>
      <email>c-lukas@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile GAUJOUX VIALA</last_name>
      <email>cecile.gaujoux.viala@chu-nimes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte TRAVERSON</last_name>
      <email>charlotte.traverson@chu-nimes.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Catastrophism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

